Reaction Details Report a problem with these data
Target
Early activation antigen CD69
Ligand
BDBM324290
Substrate
n/a
Meas. Tech.
ChEMBL_2158455 (CHEMBL5043205)
IC50
130±n/a nM
Citation
 Hopkins, BT; Bame, E; Bajrami, B; Black, C; Bohnert, T; Boiselle, C; Burdette, D; Burns, JC; Delva, L; Donaldson, D; Grater, R; Gu, C; Hoemberger, M; Johnson, J; Kapadnis, S; King, K; Lulla, M; Ma, B; Marx, I; Magee, T; Meissner, R; Metrick, CM; Mingueneau, M; Murugan, P; Otipoby, KL; Polack, E; Poreci, U; Prince, R; Roach, AM; Rowbottom, C; Santoro, JC; Schroeder, P; Tang, H; Tien, E; Zhang, F; Lyssikatos, J Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. J Med Chem 65:1206-1224 (2022) [PubMed]  Article 
Target
Name:
Early activation antigen CD69
Synonyms:
AIM | Activation inducer molecule | BL-AC/P26 | C-type lectin domain family 2 member C | CD69 | CD69_HUMAN | CD_antigen=CD69 | CLEC2C | EA1 | Early T-cell activation antigen p60 | Early activation antigen CD69 | GP32/28 | Leukocyte surface antigen Leu-23 | MLR-3
Type:
PROTEIN
Mol. Mass.:
22559.65
Organism:
Homo sapiens
Description:
ChEMBL_109097
Residue:
199
Sequence:
MSSENCFVAENSSLHPESGQENDATSPHFSTRHEGSFQVPVLCAVMNVVFITILIIALIALSVGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDSEKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKEFNNWFNVTGSDKCVFLKNTEVSSMECEKNLYWICNKPYK
  
Inhibitor
Name:
BDBM324290
Synonyms:
5-(tert-butyl)-N-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)-1,2,4-oxadiazole-3-carboxamide | US10189829, Compound 33 | US10227341, Compound 33 | US10961237, Compound 33 | US11858926, Compound 33
Type:
Small organic molecule
Emp. Form.:
C26H30N8O2
Mol. Mass.:
486.5688
SMILES:
Cn1cc(Nc2nccc(n2)-c2ccc3C(CCCCc3c2)NC(=O)c2noc(n2)C(C)(C)C)cn1
Structure:
Search PDB for entries with ligand similarity: